Gujarathi, R.; Tobias, J.; Abou Azar, S.; Keutgen, X.M.; Liao, C.-Y.
Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors. Cancers 2024, 16, 2993.
https://doi.org/10.3390/cancers16172993
AMA Style
Gujarathi R, Tobias J, Abou Azar S, Keutgen XM, Liao C-Y.
Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors. Cancers. 2024; 16(17):2993.
https://doi.org/10.3390/cancers16172993
Chicago/Turabian Style
Gujarathi, Rushabh, Joseph Tobias, Sara Abou Azar, Xavier M. Keutgen, and Chih-Yi Liao.
2024. "Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors" Cancers 16, no. 17: 2993.
https://doi.org/10.3390/cancers16172993
APA Style
Gujarathi, R., Tobias, J., Abou Azar, S., Keutgen, X. M., & Liao, C.-Y.
(2024). Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors. Cancers, 16(17), 2993.
https://doi.org/10.3390/cancers16172993